Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:2275-2281
Published online before print September 25, 2008, doi: 10.1161/ATVBAHA.108.175992
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
28/12/2275    most recent
ATVBAHA.108.175992v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hodgkinson, C. P.
Right arrow Articles by Ye, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hodgkinson, C. P.
Right arrow Articles by Ye, S.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:2275.)
© 2008 American Heart Association, Inc.


Cell Biology/Signaling

Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic Atherosclerosis

Conrad P. Hodgkinson; Ross C. Laxton; Kunal Patel; Shu Ye

From Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine, London, UK.

Correspondence to Conrad Hodgkinson, PhD, Clinical Pharmacology, William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, UK. E-mail c.hodgkinson{at}qmul.ac.uk

Objective— Diabetes is a major risk factor for coronary heart disease. Accumulation of advanced glycation end-products (AGEs) attributable to hyperglycemia in diabetics promotes the development of atherosclerosis. However, the underlying mechanisms remain unclear.

Methods and Results— The advanced glycation end-product of low-density-lipoprotein (AGE-LDL) induced proinflammatory cytokine production in human coronary artery endothelial cells and human- and mouse-macrophages. AGE-LDL stimulated cytokine synthesis was markedly reduced in mouse macrophages with a TLR4 loss-of-function mutation. Coimmunoprecipitation experiments indicated AGE-LDL interacts with TLR4, RAGE, and CD36. Incubation of cultured macrophages with TLR4, RAGE, or CD36 antibodies inhibited AGE-LDL stimulation of tumor necrosis factor (TNF){alpha} production. A competitive binding inhibitor of TLR4 blocked AGE-LDL binding to the receptor. After transfection of a HEK293 cell system with wild-type TLR4, AGE-LDL activated a signaling pathway including p38{alpha}, JNK, and ERK1 kinases and AP1, Elk1, and NF–{kappa}B transcription factors; the net result being increased cytokine production. These effects were absent when cells were transfected with empty plasmid. Two common polymorphisms in TLR4, D299G and T399I, reduced the response of TLR4 to lipopolysaccharide (LPS) but had no effect on AGE-LDL signaling.

Conclusions— These results indicate that AGE-LDL activates a TLR4-mediated signaling pathway, thus inducing proinflammatory cytokine production. This mechanism may partly explain the increased risk of atherosclerosis observed in diabetics.

There is substantial evidence indicating that glycated LDL promotes atherosclerosis. However, the underlying mechanism remains unclear. Our study shows that glycated LDL activates Toll-like receptor 4, inducing proinflammatory cytokine production. This finding is of importance for understanding why diabetics are at increased risk of developing atherosclerosis.


Key Words: diabetes • atherosclerosis • advanced glycation end-products • toll-like receptors